Skip to content
Inciteful Med
Resources About us Ask a Question

What Does a del(17p) Mutation Mean for Myeloma?

Published: | Updated:

A del(17p) mutation in multiple myeloma is a high-risk marker indicating the loss of the TP53 gene, which controls cell repair. While this makes the cancer more aggressive, modern therapies using intensive drug combinations and stem cell transplants have greatly improved patient prognosis.

Key Takeaways

  • • A del(17p) mutation is a high-risk genetic marker in multiple myeloma that deletes the important TP53 tumor suppressor gene.
  • • Your specific prognosis heavily depends on the percentage of cells affected and whether you have a single or double gene mutation.
  • • Treatment for del(17p) myeloma typically requires an aggressive upfront approach using a combination of three or four powerful drugs.
  • • Patients with high-risk genetics often need doublet maintenance therapy, which uses two medications to prevent the cancer from returning.
  • • Newer immunotherapies like CAR-T cells and bispecific antibodies are showing incredible success even in high-risk patients.

Seeing a “del(17p)” result on your FISH (Fluorescence In Situ Hybridization) test can be terrifying, and it is completely normal to feel anxious. To answer your question directly: yes, a del(17p) mutation is considered a “high-risk” marker in multiple myeloma, meaning the cancer may act more aggressively [1][2].

If you are looking for specific survival timelines, it is important to understand why your doctor cannot give you a blanket number. The impact of a del(17p) mutation varies wildly depending on whether you have a “single” or “double” hit mutation, the percentage of cells involved, and how well your cancer responds to initial therapy [3][1]. The term “prognosis” relies heavily on historical data of how myeloma used to behave. Today, modern, highly effective therapies have made high-risk myeloma much more manageable today than in the past [4][5].

What is a del(17p) Mutation?

Inside the nucleus of every cell are chromosomes, which hold your DNA. In multiple myeloma, the cancer cells often have broken or missing pieces of chromosomes. A del(17p) means there is a deletion (del) on the short arm (p) of chromosome 17 [1].

This specific missing piece is important because it is home to a crucial gene called TP53 [6]. In healthy cells, TP53 acts like the “brakes” or a quality control inspector; if a cell’s DNA becomes damaged, TP53 triggers the cell to repair itself or self-destruct [6]. When you lose TP53 due to a 17p deletion, the cancer cells lose those brakes. This makes the myeloma cells more resistant to dying off when exposed to standard chemotherapy, allowing them to grow more aggressively [1][6].

It’s Not Black and White: Important Nuances

Having a del(17p) is not a simple “yes or no” situation. There are critical details your care team will look at to understand exactly how this affects your specific prognosis:

  • The “Double Hit” Concept: You inherit two copies of chromosome 17 (one from each parent). If only one copy has the deletion, you still have one working TP53 gene. However, if the remaining copy is also mutated or missing, this is known as biallelic inactivation or “Double Hit” myeloma [3]. Double Hit myeloma is more challenging to treat than a single deletion [7][3]. Your doctor may use Next-Generation Sequencing (NGS) to check the status of your second TP53 gene [8].
  • The Percentage of Cells: Your FISH report states what percentage of the tested cells had the deletion. The mutation is generally considered an adverse risk factor at any significant level [9], but if only a tiny fraction of cells have del(17p), it may not impact your disease as severely as it would if a large majority of cells carry the mutation.

How del(17p) Changes Your Treatment Plan

Because myeloma cells with del(17p) are more stubborn, your treatment needs to be stronger and more persistent. Your care team will likely recommend a more intensified approach [10]:

  • Aggressive Upfront Treatment: Your initial treatment (induction) will likely include a combination of three or four powerful drugs (triplet or quadruplet regimens) [10][11]. Practically, this means a combination of pills you take at home and injections or IV infusions you receive at the clinic [12][13].
  • Stem Cell Transplants: For younger or fitter patients, an Autologous Stem Cell Transplant (ASCT) is a standard, highly recommended step where your own healthy stem cells are collected and returned to you after a high dose of chemotherapy [14]. For high-risk genetics like del(17p), doctors sometimes even discuss a “tandem” (double) transplant strategy, though this is evaluated on a case-by-case basis [15].
  • Doublet Maintenance: After initial treatment and a possible transplant, patients usually go on “maintenance” therapy to keep the cancer asleep. While standard-risk patients might just take one pill (like lenalidomide), patients with high-risk markers like del(17p) often require doublet maintenance [16][10]. This means taking two drugs together (often a pill and an injection) to maintain continuous pressure on the high-risk cells and prevent relapse [17][16].

The Future is Promising

While del(17p) remains a challenging feature, the treatment landscape is moving faster than ever [18]. Newer treatments like CAR-T cell therapy and bispecific antibodies are showing incredible success in treating relapsed myeloma, even in patients with high-risk genetics like del(17p) [19][20]. Your care team’s goal is to use today’s best therapies to keep your disease controlled while the next generation of myeloma treatments continues to evolve.

Frequently Asked Questions

Why is a del(17p) mutation considered high-risk in multiple myeloma?
It deletes a crucial gene called TP53, which acts as the 'brakes' for cell division. Without this gene, myeloma cells become more resistant to standard treatments and can grow more aggressively instead of dying off.
Does having a del(17p) mutation mean I have a poor prognosis?
Not necessarily. Your exact prognosis depends on whether you have a single or double mutation, the percentage of affected cells, and how well your cancer responds to modern therapies, which have significantly improved outcomes.
What is a 'Double Hit' multiple myeloma?
This occurs when both copies of chromosome 17 (one inherited from each parent) are mutated or missing. This completely inactivates the TP53 gene, making the cancer more challenging to treat than a single deletion.
How does a del(17p) mutation change my myeloma treatment?
Patients with this mutation usually require more intense therapies to keep the cancer under control. This often includes a powerful upfront combination of drugs, a possible stem cell transplant, and taking two medications together during long-term maintenance therapy.
Why might my doctor order an NGS test for the TP53 gene?
This test uses Next-Generation Sequencing (NGS) to check the status of your second TP53 gene. It is the best way to determine if you have a single mutation or a more aggressive 'Double Hit' myeloma.

Questions for Your Doctor

  • • What exact percentage of my myeloma cells have the del(17p) mutation according to the FISH test?
  • • Has my second TP53 gene been checked for mutations using Next-Generation Sequencing (NGS) to rule out a "Double Hit"?
  • • How does this high-risk marker change the triplet or quadruplet combination of drugs you are recommending for my induction therapy?
  • • Do you recommend an early Autologous Stem Cell Transplant, or potentially a tandem transplant, given my del(17p) status?
  • • Does my proposed long-term treatment plan include doublet maintenance to keep extra pressure on these high-risk cells?

Questions for You

  • • What are my personal priorities and goals for treatment when balancing a highly aggressive treatment plan with my current quality of life?
  • • Am I emotionally and practically prepared to manage a complex regimen involving a mix of daily pills, clinic injections, and potentially a stem cell transplant?
  • • Who can I bring to my appointments to help me take notes, ask questions, and advocate for the specific tests (like NGS) needed to understand my risk level?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival.

    Chin M, Sive JI, Allen C, et al.

    Blood cancer journal 2017; (7(9)):e610 doi:10.1038/bcj.2017.76.

    PMID: 29016571
  2. 2

    Natural history of multiple myeloma with de novo del(17p).

    Lakshman A, Painuly U, Rajkumar SV, et al.

    Blood cancer journal 2019; (9(3)):32 doi:10.1038/s41408-019-0191-y.

    PMID: 30846679
  3. 3

    Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome.

    De Ramón C, Rojas EA, Cardona-Benavides IJ, et al.

    British journal of haematology 2022; (199(3)):344-354 doi:10.1111/bjh.18410.

    PMID: 35983648
  4. 4

    Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

    Dimopoulos MA, Oriol A, Nahi H, et al.

    The New England journal of medicine 2016; (375(14)):1319-1331 doi:10.1056/NEJMoa1607751.

    PMID: 27705267
  5. 5

    Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.

    Chari A, Kaufman JL, Laubach J, et al.

    Blood cancer journal 2024; (14(1)):107 doi:10.1038/s41408-024-01088-6.

    PMID: 38977707
  6. 6

    Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma.

    Herrero AB, Rojas EA, Misiewicz-Krzeminska I, et al.

    International journal of molecular sciences 2016; (17(12)).

    PMID: 27916892
  7. 7

    Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance.

    Baysal M, Demirci U, Umit E, et al.

    Scientific reports 2020; (10(1)):5991 doi:10.1038/s41598-020-62885-0.

    PMID: 32249811
  8. 8

    The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma.

    Sharma N, Smadbeck JB, Abdallah N, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2021; (27(19)):5430-5439 doi:10.1158/1078-0432.CCR-21-0005.

    PMID: 34233962
  9. 9

    Conventional Cytogenetics and Interphase Fluorescence In Situ Hybridization Results in Multiple Myeloma: A Turkey Laboratory Analysis of 381 Cases.

    Aydin C, Ulas T, Hangul C, et al.

    Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2020; (36(2)):284-291 doi:10.1007/s12288-019-01215-5.

    PMID: 32425379
  10. 10

    Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

    Sonneveld P, Dimopoulos MA, Boccadoro M, et al.

    The New England journal of medicine 2024; (390(4)):301-313 doi:10.1056/NEJMoa2312054.

    PMID: 38084760
  11. 11

    Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

    Facon T, Dimopoulos MA, Leleu XP, et al.

    The New England journal of medicine 2024; (391(17)):1597-1609 doi:10.1056/NEJMoa2400712.

    PMID: 38832972
  12. 12

    Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.

    Moreau P, Attal M, Hulin C, et al.

    Lancet (London, England) 2019; (394(10192)):29-38 doi:10.1016/S0140-6736(19)31240-1.

    PMID: 31171419
  13. 13

    Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.

    Durie BGM, Hoering A, Abidi MH, et al.

    Lancet (London, England) 2017; (389(10068)):519-527 doi:10.1016/S0140-6736(16)31594-X.

    PMID: 28017406
  14. 14

    Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.

    Gao W, Jian Y, Du J, et al.

    Cancer medicine 2020; (9(21)):7819-7829 doi:10.1002/cam4.3254.

    PMID: 32881351
  15. 15

    Autologous stem cell transplantation in multiple myeloma.

    Ricciuti G, Falcone A, Cascavilla N, et al.

    Panminerva medica 2020; (62(4)):220-224 doi:10.23736/S0031-0808.20.04114-2.

    PMID: 32955179
  16. 16

    Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma.

    Ozaki S, Handa H, Koiso H, et al.

    Journal of cancer research and clinical oncology 2022; (148(1)):191-203 doi:10.1007/s00432-021-03668-6.

    PMID: 34080068
  17. 17

    Optimizing therapy for del(17p) multiple myeloma.

    Avet-Loiseau H, Richardson PG, di Bacco A

    Oncotarget 2017; (8(66)):109859-109860 doi:10.18632/oncotarget.22987.

    PMID: 29299113
  18. 18

    Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17p.

    Marcoux C, Pasvolsky O, Milton DR, et al.

    Transplantation and cellular therapy 2025; (31(1)):12.e1-12.e10 doi:10.1016/j.jtct.2024.10.011.

    PMID: 39448031
  19. 19

    Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy.

    Zhang M, Zhou L, Zhao H, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2021; (27(23)):6384-6392 doi:10.1158/1078-0432.CCR-21-2031.

    PMID: 34548316
  20. 20

    First-line anti-BCMA CAR-T cell therapy in a fragile patient with biclonal gammopathy and giant plasma cell tumor multiple myeloma with multiple comorbidities: a case report.

    Fang Y, Lin W, Shen L, et al.

    Frontiers in immunology 2025; (16()):1564774 doi:10.3389/fimmu.2025.1564774.

    PMID: 40308587

This page explains the del(17p) mutation and multiple myeloma prognosis for educational purposes only. Always consult your hematologist or oncologist to understand what your specific FISH test results mean for your individual care plan.

Stay up to date

Get notified when new research about Multiple Myeloma is published.

No spam. Unsubscribe anytime.